Smith & Nephew PLC
LSE:SN
Intrinsic Value
Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. [ Read More ]
The intrinsic value of one
SN
stock under the Base Case scenario is
1 462.4571
GBX.
Compared to the current market price of 982.3474 GBX,
Smith & Nephew PLC
is
Undervalued by 33%.
Smith & Nephew PLC's market capitalization is 8.6B GBX.
SN stock price is 982.3474 GBX.
SN stock price (982.3474 GBX) is 33% less than its Intrinsic Value (1 462.4571 GBX).
SN stock (945.4049 GBX) is 4% less than its price (982.3474 GBX). Open DCF Valuation
SN stock price (982.3474 GBX) is 50% less than its Relative Value (1 979.5093 GBX). Open Relative Valuation
SN's Revenue has grown by 6% over the past 12 months.
SN's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
SN has positive Operating Income for the last twelve months.
SN has positive Net Income for the last twelve months.
SN's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 8%.
SN's ROE (Return on Equity) has decreased in the last 3 years from 9% to 5%.
SN's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
SN has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
SN's ROE (Return on Equity) for the past 12 months is positive and is equal to 5%.
SN's Revenue has been growing by 7% per year for the last 3 years.
SN has positive three-year average ROE (Return on Equity): 7%. The company is efficient at transforming stockholders' equity into net income.
SN has positive Free Cash Flow for the last twelve months.
SN's Altman Z-Score is equal to 2.84.
SN's short-term assets (4B USD) exceed its short-term liabilties (2B USD).
SN's long-term assets (10B USD) exceed its long-term liabilties (5B USD).
SN's D/E (Debt to Equity) is very low and is equal to 0.5.
SN generates enough operating income (763m USD) to cover interest payments on its debt (104m USD).
SN has positive Gross Profit for the last twelve months.
SN has positive Net Debt. This means that the company has more debt (3B USD) than cash and short-term investments (302m USD).
Valuation Backtest
Smith & Nephew PLC
Run backtest to discover the historical profit from buying and selling
SN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Smith & Nephew PLC
Balance Sheet Decomposition
Smith & Nephew PLC
| Current Assets | 4B |
| Cash & Short-Term Investments | 302m |
| Receivables | 1.3B |
| Other Current Assets | 2.4B |
| Non-Current Assets | 6B |
| Long-Term Investments | 24m |
| PP&E | 1.5B |
| Intangibles | 4.1B |
| Other Non-Current Assets | 361m |
| Current Liabilities | 2.3B |
| Accounts Payable | 1.1B |
| Short-Term Debt | 305m |
| Other Current Liabilities | 911m |
| Non-Current Liabilities | 2.5B |
| Long-Term Debt | 2.3B |
| Other Non-Current Liabilities | 180m |
Earnings Waterfall
Smith & Nephew PLC
|
Revenue
|
5.5B
USD
|
|
Cost of Revenue
|
-1.6B
USD
|
|
Gross Profit
|
3.9B
USD
|
|
Operating Expenses
|
-3.2B
USD
|
|
Operating Income
|
763m
USD
|
|
Other Expenses
|
-500m
USD
|
|
Net Income
|
263m
USD
|
Free Cash Flow Analysis
Smith & Nephew PLC
SN Profitability Score
Profitability Due Diligence
Smith & Nephew PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Smith & Nephew PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
SN Solvency Score
Solvency Due Diligence
Smith & Nephew PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Smith & Nephew PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SN Price Targets Summary
Smith & Nephew PLC
According to Wall Street analysts, the average 1-year price target for
SN
is 1 312.365 GBX
with a low forecast of 1 085.75 GBX and a high forecast of 1 575 GBX.
Shareholder Return
SN Price
Smith & Nephew PLC
| Average Annual Return | -3.66% |
| Standard Deviation of Annual Returns | 17.83% |
| Max Drawdown | -50% |
| Market Capitalization | 8.6B GBX |
| Shares Outstanding | 874 334 976 |
| Percentage of Shares Shorted | 72% |
Company Profile
Smith & Nephew PLC
Country
Industry
Market Cap
Dividend Yield
Description
Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 18,369 full-time employees. The firm is engaged in designing and manufacturing technology. The company supports healthcare professionals to return their patients to health and mobility by helping them to perform. The company serves its customers through global franchises, which includes Orthopaedics, Sports Medicine and Ear, Nose and Throat (ENT) and Advanced Wound Management. The Orthopaedics includes a range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that allow surgeons, and Trauma products used to stabilize severe fractures and correct bone deformities. Its Sports Medicine and ENT businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a set of products to meet clinical needs, to help healthcare professionals reduce the human and economic consequences of wounds.
Contact
IPO
Employees
Officers
The intrinsic value of one
SN
stock under the Base Case scenario is
1 462.4571
GBX.
Compared to the current market price of 982.3474 GBX,
Smith & Nephew PLC
is
Undervalued by 33%.
You don't have any saved screeners yet
